News

Rhythm Pharmaceuticals reported fourth-quarter 2025 net product revenue of $57.3 million and set a near-term regulatory catalyst: a March...

Indivior posted record quarterly and full-year performance anchored by Sublocade, its long-acting buprenorphine injection for opioid use disorder. Total...

C4 Therapeutics has dosed the first patient in MOMENTUM, a Phase 2 study of the IKZF1/3 molecular glue degrader...

Kymera Therapeutics closed 2025 with two Phase 2b trials underway for KT-621, its first-in-class oral STAT6 degrader, in atopic...

argenx reported a breakout 2025: $4.2 billion in global product net sales for the year, up 90% year over...

Recursion reported fourth quarter and full-year 2025 results with a pivotal operational milestone: the company delivered its first AI-enabled...

Cardiff Oncology reported a positive randomized phase 2 readout in first-line RAS-mutated metastatic colorectal cancer, selecting the 30 mg...

Supernus Pharmaceuticals posted record fourth-quarter and full-year 2025 revenues, buoyed by newer CNS assets and the integration of Sage...

Vaxcyte has launched a comprehensive phase 3 program for VAX-31, its 31-valent pneumococcal conjugate vaccine, with head-to-head noninferiority testing...

BridgeBio Pharma reported $154.2 million in fourth-quarter revenues and $502.1 million for full-year 2025, propelled by ATTRuby’s first full...